<DOC>
	<DOCNO>NCT00048087</DOCNO>
	<brief_summary>Patients receive 250 mg Iressa mouth daily day study . Patients also receive docetaxel 30 mg/m2 vein ( IV ) day 1 weekly first 3 week course therapy . A course therapy 4 week . Patients receive docetaxel week 4 . A maximum 8 full cycle docetaxel plus Iressa plan . Patients may continue daily Iressa progressive disease and/or unacceptable toxicity .</brief_summary>
	<brief_title>Iressa/Docetaxel Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Pathologically confirm nonsmall cell lung cancer . Measurable , evaluable disease outside radiation port . ECOG performance status 02 . Adequate hematologic function define absolute neutrophil count &gt; = 1,500/mm3 , platelet count &gt; = 100,000/mm3 , WBC &gt; = 3,000/ mm3 , hemoglobin level &gt; = 9 g/dl . One prior chemotherapy regimen . This may include chemoradiation treatment . Disease progression recurrence within 6 month last dose chemotherapy first chemotherapy regimen . At least 2week recovery prior therapy toxicity . Signed informed consent . Prior CNS involvement tumor eligible previously treat clinically stable two week completion treatment . Prior Iressa EGFR inhibit agent Prior docetaxel therapy Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ . Any unresolved chronic toxicity great CTC grade 2 previous anticancer therapy . Incomplete heal previous oncologic major surgery . Concomitant use phenytoin , carbamazepine , barbiturate , rifampicin , St John 's Wort , anticoagulant . Absolute neutrophil count less 1500 x 109/liter ( L ) platelets less 100,000x 109/liter ( L ) . Serum bilirubin great 1.25 time upper limit reference range ( ULRR ) . In opinion investigator , evidence severe uncontrolled systemic disease , ( e.g. , unstable uncompensated respiratory , cardiac , hepatic , renal disease ) . A serum creatinine &gt; = 1.5 mg/dl calculate creatinine clearance &lt; = 60 cc/minute . Alanine amino transferase ( ALT ) aspartate amino transferase ( AST ) great 2.5 time ULRR demonstrable liver metastasis great 5 time ULRR presence liver metastasis . Evidence significant clinical disorder laboratory find make undesirable patient participate trial . Pregnancy breast feed The patient uncontrolled seizure disorder , active neurological disease , Grade &gt; = 2 neuropathy The patient receive investigational agent ( ) within 30 day study entry . The patient sign symptom keratoconjunctivitis sicca incompletely treat eye infection .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>